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Physiological, hyaluronan-selected intracytoplasmic sperm 
injection for infertility treatment (HABSelect): a parallel, 
two-group, randomised trial
David Miller, Susan Pavitt, Vinay Sharma, Gordon Forbes, Richard Hooper, Siladitya Bhattacharya, Jackson Kirkman-Brown, Arri Coomarasamy, 
Sheena Lewis, Rachel Cutting, Daniel Brison, Allan Pacey, Robert West, Kate Brian, Darren Griffin, Yakoub Khalaf
Summary
Background Sperm selection strategies aimed at improving success rates of intracytoplasmic sperm injection (ICSI) 
include binding to hyaluronic acid (herein termed hyaluronan). Hyaluronan-selected sperm have reduced levels of 
DNA damage and aneuploidy. Use of hyaluronan-based sperm selection for ICSI (so-called physiological ICSI 
[PICSI]) is reported to reduce the proportion of pregnancies that end in miscarriage. However, the effect of PICSI on 
livebirth rates is uncertain. We aimed to investigate the efficacy of PICSI versus standard ICSI for improving livebirth 
rates among couples undergoing fertility treatment.
Methods This parallel, two-group, randomised trial included couples undergoing an ICSI procedure with fresh 
embryo transfer at 16 assisted conception units in the UK. Eligible women (aged 18–43 years) had a body-mass index 
of 19–35 kg/m² and a follicle-stimulating hormone (FSH) concentration of 3·0–20·0 mIU/mL or, if no FSH 
measurement was available, an anti-müllerian hormone concentration of at least 1·5 pmol/L. Eligible men (aged 
18–55 years) had not had a vasovasostomy or been treated for cancer in the 24 months before recruitment and were 
able, after at least 3 days of sexual abstinence, to produce freshly ejaculated sperm for the treatment cycle. Couples 
were randomly assigned (1:1) with an online system to receive either PICSI or a standard ICSI procedure. The primary 
outcome was full-term  (≥37 weeks’ gestational age) livebirth, which was assessed in all eligible couples who completed 
follow-up. This trial is registered, number ISRCTN99214271.
Findings Between Feb 1, 2014, and Aug 31, 2016, 2772 couples were randomly assigned to receive PICSI (n=1387) or 
ICSI (n=1385), of whom 2752 (1381 in the PICSI group and 1371 in the ICSI group) were included in the primary 
analysis. The term livebirth rate did not differ significantly between PICSI (27·4% [379/1381]) and ICSI (25·2% 
[346/1371]) groups (odds ratio 1·12, 95% CI 0·95–1·34; p=0·18). There were 56 serious adverse events in total, 
including 31 in the PICSI group and 25 in the ICSI group; most were congenital abnormalities and none were 
attributed to treatment.
Interpretation Compared with ICSI, PICSI does not significantly improve term livebirth rates. The wider use of 
PICSI, therefore, is not recommended at present.
Funding National Institute for Health Research Efficacy and Mechanism Evaluation Programme.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Globally, between 2008 and 2010, more than 4·7 mil­
lion treatment cycles of assisted reproduction 
techniques were performed, of which around half 
involved intracytoplasmic sperm injection (ICSI),1 
leading to the birth of 1·14 million babies.2 ICSI, which 
was originally developed to treat male infertility,3 is 
normally used to treat men with few or abnormal 
sperm and is associated with livebirth rates of around 
24% per treatment cycle, a frequency that has remained 
unchanged in the past decade.1,2 ICSI is becoming the 
preferred treatment for infertility, although it might 
not confer any substantial advantage over in­vitro 
fertilisation (IVF) in cases of non­male­factor 
infertility.1 Additionally, unlike IVF, ICSI does not help 
prevent dysfunctional sperm from entering the egg.4 
Screening sperm on the basis of quality before ICSI is 
one possible solution to this problem,5 potentially 
assis ting embryologists in selecting the best sperm for 
injection and accordingly improving treatment success 
rates.
Hyaluronic acid (herein termed hyaluronan) is a bio­
logically active molecule that is also a major component 
of the extracellular matrix surrounding the oocyte­
cumulus complex.6 Several small clinical studies,7–11 
including three randomised trials,7–9 reported that ICSI 
with hyaluronan­selected sperm (so­called physiological 
ICSI [PICSI]) improved embryo quality and livebirth 
rates and decreased miscarriage rates compared with 
ICSI with sperm selected using standard methods. In 
Lancet 2019; 393: 416–22
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these studies, couples who benefited most from 
treatment had low hyaluronan–sperm binding scores, 
and in one study,11 baseline hyaluronan–sperm binding 
scores were used to decide who should be treated with 
PICSI.
We aimed to test the hypothesis that PICSI improves 
full­term (≥37 weeks’ gestational age) livebirth rates 
compared with ICSI.
Methods
Study design and participants
HABSelect was a parallel, two­group, randomised trial at 
16 assisted conception units licensed by the Human 
Fertilisation and Embryology Authority (HFEA) in the 
UK.12 Eligible couples were undergoing an ICSI procedure 
with fresh embryo transfer. Eligible women were aged 
18–43 years; had a body­mass index (BMI) between 
19 kg/m² and 35 kg/m²; and had a follicle­stimulating 
hormone (FSH) concentration between 3·0 mIU/mL and 
20·0 mIU/mL or, if no FSH mea surement was available, 
an anti­müllerian hormone (AMH) concentration of at 
least 1·5 pmol/L. Eligible men were aged 18–55 years; 
had not had a vasovasostomy or been treated for cancer in 
the 24 months before recruitment; and were able, after at 
least 3 days of sexual abstinence, to produce freshly 
ejaculated sperm for the treatment cycle. Couples were 
excluded if they were using donor or frozen gametes or 
undergoing split IVF–ICSI.
This study was approved by the National Research Ethics 
Service (approval number 13/YH/0162). Final approval for 
participation in the trial was obtained from the doctor 
(or team) in charge of treatment. Written informed consent 
was obtained from all participants.
Randomisation and masking
Embryologists at research sites randomly assigned (1:1) 
couples, using an online randomisation system, to under­
go PICSI or standard ICSI. Randomisation was done by 
minimisation with a random component, stratified by site, 
to balance for maternal age (<35 years vs ≥35 years), 
paternal age (<35 years vs ≥35 years), previous mis ­
carriages (none vs one or two vs more than two), and 
concentrations of hormonal indicators of ovarian reserve 
(FSH <6·0 mIU/mL vs ≥6·0 mIU/mL; AMH <17·0 pmol/L 
vs ≥17·0 pmol/L). The randomisation system revealed 
allocations only after treatment assignment was complete. 
Trial participants, research staff collecting outcome data, 
and all trial team members who contributed to the statistical 
analysis plan were masked to treatment allocation until the 
database was locked and the statistical analysis plan was 
signed off. It was impractical to conceal allocation from the 
embryologists performing the intervention. 
Procedures
Women at each treatment centre underwent ovarian 
stimulation with long­agonist, short­agonist, or antag­
onist regimens according to local protocols.12 Similarly, 
egg retrieval, laboratory culture, and ICSI followed locally 
approved protocols.12 PICSI plates were obtained from 
Origio (Reigate, UK), and sperm selection was done 
according to the supplier’s instructions and only after 
local training in the procedure. Treatments concluded 
with the transfer of one to three fresh embryos on days 3 
or 5 after fertilisation, which were selected on the basis of 
their morphology.
We calculated hyaluronan–sperm binding scores on 
the day of treatment for prepared, washed semen using 
Research in context
Evidence before this study
Although the advent of intracytoplasmic sperm injection (ICSI) 
has transformed the treatment of male infertility, success rates 
in terms of livebirths per treated couple have remained 
reasonably static in the past 10 years at around 25%. Demand 
for fertility treatment around the world is rising, and more 
than half of all treatment cycles now involve ICSI. Research 
aimed at increasing livebirth rates has focused mainly on 
women, but an increasing interest in male fertility has led to 
the development of sperm selection techniques to allow 
embryologists to select, with confidence, the best sperm for 
ICSI and potentially improve success rates. The naturally 
occurring organic polymer, hyaluronic acid (herein termed 
hyaluronan), is thought to select sperm with good DNA 
integrity and low rates of aneuploidy. Hyaluronan-based 
selection of sperm (so-called physiological ICSI [PICSI]) has 
been reported to increase livebirth rates and decrease 
miscarriage rates, and a multicentre randomised controlled 
trial of  PICSI efficacy, although considerably larger than 
previous trials, did not report livebirth rates. Furthermore, 
the importance of the hyaluronan–sperm binding score in 
determining the likely benefit of sperm selection to the couple 
remains uncertain.
Added value of this study
To our knowledge, HABSelect is the largest randomised trial 
of PICSI to date and the first to provide a robust measure of 
livebirth. PICSI did not significantly increase the term 
livebirth rate compared with standard ICSI, but a significant 
decrease was observed in miscarriage rates among couples in 
the PICSI group. There were no differences between groups 
in any other outcome, and the hyaluronan–sperm binding 
score did not seem to predict or affect the outcomes of 
treatment.
Implications of all the available evidence
All of the available evidence suggests that hyaluronan-based 
sperm selection decreases miscarriage rates after ICSI, but not 
sufficiently to affect livebirth rates. The mechanism through 
which PICSI might reduce rates of miscarriage is being 
investigated in an ongoing independent analysis.
For the Human Fertilisation and 
Embryology Authority see 
https://www.hfea.gov.uk
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the Hydak slide (Origio, Reigate, UK), according to 
the supplier’s instructions. These scores were calculated 
as the number of immobilised sperm divided by the total 
number of sperm, multiplied by 100. To aid comparisons 
with other studies that calculated hyaluronan–sperm 
binding scores,8,11,13 we stratified the scores into those that 
were 65% or less and those greater than 65%. Follow­up 
data were collected according to approved, trial­specific 
case report forms12 and from routine patient records.
Outcomes
The primary outcome was full­term (≥37 weeks’ 
gestational age) livebirth. Secondary outcomes were 
clinical pregnancy (defined as the presence of a fetal 
heartbeat or gestational sac at 6–9 weeks after fresh 
embryo transfer), miscarriage (defined as pregnancy loss 
after confirmation of clinical pregnancy), and livebirth 
before 37 weeks’ gestational age (henceforth described as 
premature birth).
Statistical analysis
On the basis of HFEA longitudinal data, we estimated 
that the term livebirth rate in the ICSI group would be 
about 24%. To detect a 5% increase (from 24% to 29%) 
in the PICSI group, with 90% power at the 5% signif­
icance level, 3266 couples were required. We aimed to 
recruit 3700 couples to allow for a 10% dropout rate. 
How ever, because of poorer than expected recruitment, 
in October, 2015, the trial steering committee (who were 
masked to treatment assignment) recommended that the 
target for power should be revised to 80%, meaning that 
2444 couples were required for the primary analysis.
Primary and secondary endpoints were assessed in 
the modified intention­to­treat population, which 
included all couples who completed follow­up, analysed 
in the groups to which they were randomly assigned. 
Our statistical analysis plan prespecified that if more 
than 5% of primary outcome data were missing, we 
would do sensitivity analyses to investigate the effects 
of departures from the missing­at­random assumption 
on our conclusions. Primary analysis of primary and 
secondary outcomes was done using a mixed effects 
logistic regression model adjusted for the minimisation 
factors (maternal age, paternal age, number of previous 
miscarriages, and hormonal indicators of ovarian 
reserve) and a random effect for site. We used cubic 
splines with three knots (knot locations based on 
Harrell’s recommendations) to adjust for maternal and 
paternal ages.14,15 A prespecified sensitivity analysis of 
the primary outcome was also done, with adjustment 
for additional covariates, including mother’s BMI, 
ethnicity, history of pregnancy, smoking status, and 
hormonal treatment received (long agonist, short 
agonist, or antagonist).
Effects of treatment are presented as odds ratios (ORs) 
with 95% CIs. Absolute risk differences with 95% CIs 
were calculated from unadjusted logistic regression 
models with the delta method.16
We did prespecified subgroup analyses to investigate 
whether the effect of treatment on the primary outcome 
was modified by hyaluronan–sperm binding score, 
maternal age, previous miscarriage, or hormonal indi­
cators of ovarian reserve. Following database locking, 
unmasking, and analysis, we were alerted to an 
unexpected and significant difference in miscarriage 
rates between trial groups. Therefore, we did a post­hoc 
subgroup analysis to investigate whether hyaluronan–
sperm binding score, maternal age, previous miscarriage, 
or hormonal indicators of ovarian reserve modified the 
effect of treat ment on miscarriage rates. All analyses were 
done with Stata version 14. An α value of 5% or less was 
considered significant. The full statistical analysis plan is 
available in the appendix.
Role of the funding source
The funder of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author and 
statistical support authors (GF and RH) had full access 
to all the data in the study, and the corresponding author 
had final responsibility for the decision to submit for 
publication.
Results
Between Feb 1, 2014, and Aug 31, 2016, 2772 couples were 
randomly assigned to receive PICSI (n=1387) or standard 
See Online for appendix
Figure: Trial profile
PICSI=physiological intracytoplasmic sperm injection. ICSI=intracytoplasmic sperm injection. IVF=in-vitro 
fertilisation. *Three received IVF, two received IVF–ICSI split cycle, and 36 received ICSI. †Five received IVF, 
three received IVF–ICSI split cycle, and one received PICSI. ‡These individuals were found to not meet eligibility 
criteria after randomisation. 
2772 randomly assigned 
6700 patients assessed for eligibility 
1385 allocated to standard ICSI
1376 received allocated intervention
9 did not receive allocated intervention†
14 excluded
9 lost to follow-up
5 randomised in error‡ 
1371 included in primary analysis 
1387 allocated to PICSI
1346 received allocated intervention
41 did not receive allocated intervention*
6 excluded
5 lost to follow-up
1 randomised in error‡ 
1381 included in primary analysis   
3928 excluded
1323 did not meet eligibility criteria
795 declined to participate
484 consented and not randomised
700 other reasons
626 no further contact
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ICSI (n=1385; figure). Six couples who did not meet 
eligibility criteria were excluded after randomisation, and 
14 couples were lost to follow­up; thus, 2752 couples were 
included in the primary analysis (figure).
Baseline and treatment characteristics were well 
balanced between groups (tables 1, 2). The median 
sperm concentration before treatment (11·0 × 10⁶ per mL 
[IQR 3·5–30·0]; table 1) was lower than the WHO lower 
reference value (5th centile: 15·0 × 10⁶ per mL)17 but had 
risen to this concentration by the day of treatment 
(table 2).
The term livebirth rate was 27·4% in the PICSI group 
and 25·2% in the standard ICSI group (OR 1·12, 95% CI 
0·95–1·34; p=0·18; table 3; appendix). Similar results 
were obtained in the prespecified sensitivity analysis of 
the primary outcome (table 3). We did not find evidence 
of differential effects of treatment on the primary 
outcome according to hyaluronan–sperm binding scores, 
maternal age, previous miscarriage, maternal FSH 
concen trations, or paternal sperm concentrations 
(appendix).
The proportions of couples with clinical pregnancy or 
premature birth were not significantly different between 
groups (table 3). By contrast, the proportion of couples 
whose clinical pregnancy ended in miscarriage was 
significantly lower in the PICSI group than in the ICSI 
group (table 3; appendix). We found no evidence of 
differential effects of treatment on miscarriage rates 
according to hyaluronan–sperm binding scores, maternal 
age, previous miscarriage, maternal FSH or AMH con­
cen trations, or paternal sperm concentrations (appendix). 
There were no differences between groups in the 
exploratory endpoints of fertilisation and biochemical 
pregnancy (table 3).
56 serious adverse events were recorded during the 
study, affecting 31 (2%) of 1386 patients in the PICSI 
PICSI (n=1386) ICSI (n=1380)
Male partner
Age (years) 36·1 
(5·5; n=1386)
35·9 
(5·4; n=1380)
≥35 years 812/1386 (59%) 803/1380 (58%)
BMI (kg/m²) 27·3 
(4·6; n=570)
27·0 
(4·2; n=549)
Ethnicity
White 1047/1386 (76%) 1078/1380 (78%)
Asian 193/1386 (14%) 166/1380 (12%)
Black 49/1386 (4%) 45/1380 (3%)
Other 36/1386 (3%) 45/1380 (3%)
Not stated 61/1386 (4%) 46/1380 (3%)
Current smoker 68/1365 (5%) 65/1353 (5%)
Cigarettes per day 8·0 (5·5; n=63) 8·5 (5·2; n=59)
Consumes alcohol 771/1304 (59%) 791/1300 (61%) 
Units per week 7·7 (6·3; n=724) 7·7 (6·8; n=740)
Recreational drug use 7/1303 (1%) 6/1286 (<1%)
Sperm concentration 
(×10⁶ per mL)*
11·0 
(3·5–29·5; n=1335)
11·0 
(3·6–31·0; n=1338)
ICSI recommended based 
on semen assessment
1268/1320 (96%) 1245/1310 (95%)
Female partner
Age (years) 33·6 
(4·4; n=1386)
33·7 
(4·3; n=1380)
≥35 years 618/1386 (45%) 617/1380 (45%)
BMI (kg/m²) 24·7 
(3·5; n=1368)
24·4 
(3·5; n=1360)
Ethnicity
White 1029/1386 (74%) 1049/1380 (76%)
Asian 214/1386 (15%) 189/1380 (14%)
Black 45/1386 (3%) 46/1380 (3%)
Other 52/1386 (4%) 55/1380 (4%)
Not stated 46/1386 (3%) 41/1380 (3%)
Current smoker 31/1375 (2%) 20/1368 (1%)
Cigarettes per day 6·4 (3·3; n=28) 6·3 (3·6; n=20)
Consumes alcohol 646/1340 (48%) 673/1328 (51%) 
Units per week 5·1 (4·3; n=614) 5·1 (4·7; n=634)
Recreational drug use 1/1317 (<1%) 1/1302 (<1%)
Data are mean (SD) or n/N (%), unless otherwise indicated. n refers to the number 
of patients for whom data were available. PICSI=physiological intracytoplasmic 
sperm injection. ICSI=intracytoplasmic sperm injection. BMI=body-mass index. 
*Data are median (IQR).
Table 1: Baseline characteristics
PICSI (n=1386) ICSI (n=1380)
Semen pre-preparation assessment
Semen volume (mL) 2·9 (1·4; 
n=1338)
3·0 (1·5; 
n=1332)
Sperm concentration 
(×10⁶ per mL)*
14·7 (4·0–35·0; 
n=1236)
16·0 (5·0–36·4; 
n=1223)
Forward progressive motility (%) 39·5 (20·1; 
n=1216)
40·8 (20·3; 
n=1198)
Semen post-preparation assessment
Sperm processing method
Swim-up 18/1343 (1%) 19/1337 (1%)
Density gradient 
centrifugation
1044/1343 (78%) 1028/1337 (77%)
Direct centrifugation 191/1343 (14%) 198/1337 (15%)
Other 89/1343 (7%) 90/1337 (7%)
Not processed 1/1343 (<1%) 2/1337 (<1%)
Forward progressive motility (%) 68·6 (28·1; 
n=1161)
69·5 (27·5; 
n=1140)
Hyaluronan–sperm binding score
≤25% 86/963 (9%) 74/947 (8%)
26–65% 188/963 (20%) 181/947 (19%)
>65% 689/963 (72%) 692/947 (73%)
Oocyte collection
Number of eggs collected 
per couple
10·9 (6·3; 
n=1345)
10·8 (6·3; 
n=1337)
Number of metaphase II oocytes 
injected with sperm
8·7 
(5·1; n=1341)
8·5 
(5·1; n=1331)
Data are mean (SD) or n/N (%), unless otherwise stated. n refers to the number of 
patients for whom data were available. PICSI=physiological intracytoplasmic sperm 
injection. ICSI=intracytoplasmic sperm injection. *Data are median (IQR). 
Table 2: Treatment characteristics
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group and 25 (2%) of 1380 patients in the standard 
ICSI group (appendix). There were two suspected 
unexpected serious adverse reactions, including 
one case of hypo spadias in the PICSI group and one of 
achondroplasia in the ICSI group; neither was attributed 
to treatment.
We did an exploratory analysis to investigate whether 
trial sampling was representative of national trends and 
to ascertain the individual contribution of each clinic to 
the study population. We compared mean term livebirths 
per embryo transfer, obtained for each site from publicly 
available HFEA data, with the equivalent values in this 
study. The mean number of term livebirths per embryo 
transfer across all sites was 0·26 (SD 0·05) when 
calculated with HFEA data and 0·23 (0·06) when 
calculated with trial data (appendix). 26% of couples in 
the trial were randomised at one site, which had a mean 
number of livebirths per embryo transfer of 0·23 for 
both HFEA and trial data. The overall similarity between 
mean numbers of term livebirths per embryo transfer 
calculated with HFEA or trial data suggests that neither 
multiple­site sampling nor relative site contribution 
affected trial outcomes.
Discussion
In this multicentre clinical trial, PICSI did not increase 
the term livebirth rate compared with standard ICSI, 
and there was no difference between groups in either 
clinical pregnancy or premature birth. However, we 
observed a significant reduction in miscarriage with 
PICSI compared with standard ICSI.
Although our results are largely consistent with those 
of previous reports,7–11 we have provided, for the first 
time, a robust measure of livebirth following an 
hyaluronan­based sperm selection procedure. Previous 
studies5,7,9,11,13 of hyaluronan­based sperm selection were 
inconclusive with respect to livebirth outcome, and 
with the exception of three studies,8,9,11 were not 
randomised trials or were underpowered. The largest 
randomised trial8 of hyaluronan­based sperm selection 
before this study did not report livebirth rate. Similar 
to previous studies,8,11 we stratified hyaluronan–sperm 
binding scores into low­binding and high­binding cat­
egories. We did not, however, consider hyaluronan–
sperm binding scores in treatment choice or offer 
PICSI only to those with lower baseline hyaluronan–
sperm binding scores. Instead, to make the results of 
the trial generalisable to all couples undergoing an 
ICSI procedure, we relied on subgroup analysis of the 
stratified sample to indicate whether hyaluronan–
sperm binding scores affect clinical outcomes of 
treatment. Whereas we found no association between 
hyaluronan–sperm binding scores and treatment 
outcomes, Mokanszki and colleagues11 reported a 
significantly increased livebirth rate in the subgroup 
with lower (<60%) hyaluronan–sperm binding scores 
compared with the subgroup with higher (≥60%) 
scores. However, the sample size of that study was 
small (n=250), and participants were not randomly 
assigned to treatment. Given that we saw no effect of 
hyaluronan–sperm binding scores on outcome, 
increasing sample size further or restricting the 
intervention to couples with lower hyaluronan–sperm 
binding scores to rule it out as a factor in treatment 
choice seems unnecessary.
Although this study was not powered to investigate 
miscarriage, we found that the proportion of couples 
with clinical pregnancy that ended in miscarriage was 
lower in the PICSI group than in the standard ICSI 
group, and that the confidence interval for the absolute 
difference between groups was narrow. This reduction 
in miscarriage with PICSI has been observed in previous 
studies.8,11 Livebirth is a far more common outcome of 
the reproductive cycle (natural and assisted) than 
miscarriage; hence, the confidence interval for the 
absolute risk difference was wider for livebirth than for 
PICSI ICSI Absolute difference 
(95% CI)
Odds ratio 
(95% CI) 
p value
Term livebirth
Primary analysis* 27·4% (379/1381) 25·2% (346/1371) 2·2% (–1·1 to 5·5) 1·12 (0·95 to 1·34) 0·18
Sensitivity analysis† 27·5% (379/1379) 25·3% (346/1370) 2·2% (–1·1 to 5·5) 1·13 (0·95 to 1·34) 0·17
Secondary endpoints
Clinical pregnancy 35·2% (487/1382) 35·7% (491/1375) –0·5% (–4·0 to 3·1) 0·98 (0·84 to 1·15) 0·80
Miscarriage 4·3% (60/1381) 7·0% (96/1371) –2·7% (–4·4 to –0·9) 0·61 (0·43 to 0·84) 0·003
Premature birth 3·3% (46/1381) 3·3% (45/1371) 0·0% (–1·3 to 1·4) 1·02 (0·67 to 1·55) 0·94
Exploratory endpoints
Fertilisation rate (%)‡ 66% (24·0) 69% (24·0) 3·0% (–0·47 to 6·5) 1·15 (0·98 to 1·34) 0·09
Biochemical pregnancy 39·5% (546/1383) 39·5% (544/1377) 0·0% (–4·0 to 4·0) 1·00 (0·86 to 1·17) 0·99
Data are % (n/N), unless otherwise stated. PICSI=physiological intracytoplasmic sperm injection. ICSI=intracytoplasmic sperm injection. *Adjusted for maternal age, previous 
miscarriage, and hormonal indicators of ovarian reserve. †Adjusted for hyaluronan–sperm binding score, maternal age, previous miscarriage, and hormonal indicators of 
ovarian reserve. Odds ratios are shown alongside absolute differences. ‡Data are mean (SD); denominators were 1386 for the PICSI group and 1380 for the ICSI group. 
Table 3: Trial outcomes
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miscarriage. This statistical effect helps to explain why 
the absolute improvement in term livebirth rate, 
although similar to the absolute reduction in miscarriage, 
was not significant in this study. The difference of 
around 2·5% has a greater effect on miscarriage than on 
term livebirth when presented as a relative difference. 
Future research should more precisely establish the 
patient and sample characteristics that underpin the 
reduction in miscarriage observed in this study, and the 
mechanism responsible. An independent analysis of 
trial data to shed light on why PICSI achieved lower 
miscarriage rates than did standard ICSI in this study 
will be reported elsewhere.
This study has several strengths. The study had clearly 
defined outcomes, and all participants and investigators, 
except for embryologists, were masked to treatment 
assignment. Moreover, we used locally approved, robust 
operating standards throughout, which helped mini­
mise any potential lo gistical and technical limitations 
resulting from the multicentre design. Despite the 
approved reduction in power, HABSelect still random­
ised 2772 couples, which was more than three times 
the number in the next largest trial of PICSI.8 We are 
there fore confident that the primary outcome was 
robust. Although embryologists were necessarily not 
masked to treatment allocation, it is unlikely that they 
could have biased the assessment of outcomes, which 
were objectively measured. They could have formed a 
view about the effectiveness of treatment that might 
have affected equipoise and influenced recruitment. 
However, given that allocation concealment was main­
tained through out by use of online randomisation after 
recruitment, it was not possible for embryologists to 
influence the characteristics of participants allocated to 
one trial group compared with the other.
Reviews and meta­analyses considering the efficacy of 
hyaluronan­based sperm selection for ICSI have been 
equivocal.5,18,19 Based on our study design, we can say with 
confidence that PICSI is not superior to standard ICSI for 
improving term livebirth rates, despite the reduction in 
miscarriage. Wider in­service application of PICSI is 
therefore unjustified at this time.
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